DIFFERENCE IS SIGNIFICANT

Slides:



Advertisements
Similar presentations
Infectious hepatitis Clinical manifestations: Asymptomatic Acute Chronic Asymptomatic carrier Hepatic failure Cirrhosis Hepatocellular carcinoma.
Advertisements

C-Reactive Protein: What Is It?  Marker of inflammation made in liver 1  Acute-phase response  Illness or injury 2  Adipocyte release of cytokines.
V. Petrenkiene*, D. Petrauskas L. Kupcinskas, Lithuanian University of Health sciences Clinic of Gastroenterology Kaunas Utility of non-invasive markers.
Slide Source: Lipids Online Slide Library CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease: Recommendations.
Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complications of sulfur mustard poisoning & its correlation with severity.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
F ATTY L IVER Shahin Merat, M.D. Associate Professor of Medicine Digestive Disease Research Center, Tehran University of Medical Sciences, 8 th International.
IL FEGATO IL PANCREAS…..ed I loro segnali
Multiplex Genetic Test in Liver Detoxification Function for Predicting Liver Disease Progression Ran Oren, Hava Peretz, Sigal Fishman, Guy Rosner, Zamir.
Non-alcoholic Fatty Liver Disease
Evaluating the Patient With Abnormal Liver Tests-2 פרופ ' צבי אקרמן מבית חולים הדסה הר הצופים.
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
Clinical Trial Results. org Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity.
DIFFUSE LIVER DISEASE BN Dr. Bengt Norén M. D, Med Lic. Dep. of Radiology and CMIV University Hospital Linköping.
C - reactive protein. C - reactive protein ( CRP ) ◌ C-reactive protein was originally discovered as a substance in the serum of patients with acute inflammation.
By: Kristin Izzo Preceptors: Elizabeth Koustis, MS, RD Pamela Jessup, MS, RD WADE PARK NUTRITION CLINIC.
Liver Seminar for Health Plan Case Managers September 23, 2008 October 2, 2008.
Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis 소화기내과 R3 신아리 1.
Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease : The St Francis Heart Study Randomized Clinical Trial Temitope Foster,
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
F. 정 회 훈 Am J Gastroenterol 2012;107:46-52 Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy:
Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Giovanni Targher, Lorenzo Bertolini, Felice Poli,
Pasi Erkkilä and Akseli Koskela
Hepatic Steatosis in patients with Autoimmune Hepatitis (AIH) – prevalence, progression and possible significance C. Salmon*1, B.Hoeroldt2, A. Dube3,
World Congress of Cardiology Scientific Sessions, 2014; Melbourne, Australia, 4-7 May 2014 PW 109 RATIO OF PROINFLAMMATORY AND ANTIINFLAMMATORY ​​FACTORS.
The role of unknown risk factors in coronary heart disease
results of the METAFIB study
Diagnostic accuracy and statistical significance
Results from the intermountain heart collaborative study
Effect of Periodontal Therapy on GCF and Serum Levels of High-Sensitive C- reactive protein in Chronic Periodontitis Patients Alaa M Attia: Associate.
P010 HEART, VESSELS & DIABETES – THE EUROPEAN CONFERENCE, LISBON CONGESS CENTRE, DECEMBER ISOLATED ISCHEMIA OF MYOCARDIUM OR COMBINED WITH.
PLASMA HOMOCYSTEINE LEVELS AS A PREDICTOR
Elevated Circulating Levels of Inflammatory Markers in
Serum ceruloplasmin, copper, zinc levels and Cu/Zn ratio in malignancy
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Vrushali Patwardhan, Dinesh Kumar, Varun Goel, Sarman Singh
BACKGROUND RESULTS OBJECTIVES METHODS CONCLUSIONS REFERENCES
Gastrointestinal and liver diseases
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Presented By: Sally Saad Mandour Esawy
Underwriting Screening Liver Test Abnormalities:
Chronic viral hepatitis type B with “ground glass” cells
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
Starting Strong: Initial Evaluation of the Patient With HCV
More Than Meets the Eye: Identifying Who Is at Risk for NASH
Alcoholic foamy degeneration with early alcoholic cirrhosis
Chapter 3 Fatty Liver Diseases 1 Alcoholic steatosis Case 3.1.
Non-invasive diagnosis of non-alcoholic fatty liver disease
NAFLD, Obesity, and Bariatric Surgery
Figure 1 Proposed algorithm for the management
Volume 149, Issue 2, Pages (August 2015)
Alcoholic liver disease in intensive care
Impact of metabolic risk factors on HCC
by Agata Juszczak, Rebecca Pryse, Andrew Schuman, and Katharine R Owen
Hepatitis C: After the Diagnosis
Care of Patients with Liver Problems
Sedentary time was higher in non-alcoholic fatty liver disease (NAFLD) than healthy controls with fewer sedentary to active transitions (data reported.
Hypothesised conceptual framework of the association between lung and vascular events. Hypothesised conceptual framework of the association between lung.
Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis  A.D. Pearle, M.D.,
Figure 1 NAFLD pathogenesis
Volume 64, Issue 6, Pages (June 2016)
The metabolomic window into hepatobiliary disease
Infliximab trough levels above 7 μg/mL in inflammatory bowel disease treated with infliximab: Better control of inflammation without increased risk of.
Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.
PowerPoint 16:9 Screen Ratio Template *
Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.
Fig. 4: Schematic, initial diagnostic algorithm for a patient presenting with mild aminotransferase abnormality. Fig. 4: Schematic, initial diagnostic.
Presentation transcript:

DIFFERENCE IS SIGNIFICANT HIGHLY SENSITIVE C-REACTIVE PROTEIN AS A NON-INVASIVE MARKER OF NON ALCOHOLIC FATTY LIVER DISEASE PREET SHAH Jaslok Hospital and Research Centre, Mumbai NAFLD N MEAN(±SD) MANN WHITNEY P VALUE YES 27 6.7±3.5 46.5 0.015 NO 8 4±1.7 DIFFERENCE IS SIGNIFICANT Introduction: Non alcoholic fatty liver disease(NAFLD)causes increased delivery of fatty acids to the liver and inadequate fatty acid oxidation. It triggers necro-inflammatory response in the liver, leading to fibrosis and cirrhosis. Chronic low-grade inflammation plays a crucial role in cardiovascular events and DM. As NAFLD is associated with these diseases, it can be hypothesized that chronic inflammation may be the second hit to the liver for developing NAFLD. Highly Sensitive C-Reactive Protein(hs-CRP)is an acute phase reactant and a marker of inflammatory state. D Results: Mann Whitney test was applied to see the association of high sensitivity C-reactive protein (hs-CRP) and NAFLD. Out of 100 subjects,35 had elevated hsCRP levels. A higher mean value of 6.7±3.5 was seen in the NAFLD patients, as compared to those in whom NAFLD was absent, who had a mean value of 4±1.7. The p-value between these 2 groups was 0.015 which was significant. Conclusion: hsCRP is a useful non-invasive marker of NAFLD. Method: The association of hs-CRP and NAFLD in 100 subjects at a tertiary care centre was studied. These included inpatients as well as outpatients. Patients consuming alcohol, those using drugs known to cause hepatic steatosis, those having a medical condition known to cause hepatic steatosis, and those with viral hepatitis were excluded. Ultrasonography of the abdomen was used to detect fatty liver, and hs-CRP levels were tested using spectrophotometry method. Data was analysed using statistical analysis tools in SPSS software. Mann Whitney test was used to assess the association of hs-CRP and NAFLD. A p-value of <0.05 was considered significant. References: Yeniova AO, Küçükazman M, Ata N, et al. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease. Hepatogastroenterology. 2014;61(130):422-5 Nigam P, Bhatt SP, Misra A, et al. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS ONE. 2013;8(1):e49286